Press Announcements

Note: Press announcements from 2004-2012, 2013-2016, 2017, 2018-2020, 2021, 2022, and 2023 are available through the FDA.gov Archive. Some links in press announcements may no longer be active. For more information, contact FDA’s Office of Media Affairs at 301-796-4540.

July 2026

• July 17, 2026 - FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
• July 15, 2026 - FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in Horses
• July 10, 2026 - FDA Proposes Rule to Modernize Drug Manufacturing Registration
• July 1, 2026 - FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

June 2026

• June 30, 2026 - FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
• June 29, 2026 - FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing
• June 26, 2026 - FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health
• June 17, 2026 - FDA Approves First Single-Dose Generic Treatment for Influenza
• June 16, 2026 - FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
• June 15, 2026 - FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes

Pagination

• Current page 1
• Page 2
• Page 3
• Page 4
• Page 5
• Page 6
• Page 7
• Page 8
• Page 9
• …
• Next page ››
• Last page Last »